Novel screening platform for O-GlcNAc transferase substrate-specific inhibitors to combat aging-related diseases

用于对抗衰老相关疾病的 O-GlcNAc 转移酶底物特异性抑制剂的新型筛选平台

• 批准号: 10475192
• 负责人: Arielis Estevez Davila
• 金额: $ 7.19万
• 依托单位: UNIVERSITY OF WISCONSIN-MADISON
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10475192
• 关键词: Active Sites; Address; Affect; Aging; Alzheimer' s Disease; Binding; Biological Assay; Biological Process; Cells; Chemicals; Diabetes Mellitus; Disease; Drug Targeting; Enzymes; Epigenetic Process; Fluorescence Resonance Energy Transfer; Generations; Homeostasis; Human; Huntington Disease; In Vitro; Label; Lead; Libraries; Link; Malignant Neoplasms; Metabolism; Modeling; Modification; O-GlcNAc transferase; Performance; Play; Post-Translational Protein Processing; Proteins; Rapid screening; Reporting; Role; Series; Structure; base; combat; experimental study; glycosylation; high throughput screening; inhibitor; innovation; interest; new therapeutic target; novel; peptide O-linked N-acetylglucosamine-beta-N-acetylglucosaminidase; process optimization; protein degradation; screening; side effect; small molecule; therapeutic development; tool

Project Summary The O-linked β-N-acetylglucosamine (O-GlcNAc) is an essential post-translational modification found in thousands of proteins involved in a broad range of important biological processes, including epigenetics, metabolism, and protein degradation. The O-GlcNAc modification is dynamically added and removed by a single pair of human enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively. Dysregulation of O-GlcNAcylation has been detected in many aging-related diseases including cancer, diabetes, Alzheimer’s and Huntington’s disease. To date, several effective active-site inhibitors have been reported for OGT and OGA, but they are likely to induce undesired side effects as these essential enzymes regulate O-GlcNAc dynamics on thousands of protein substrates. Currently, there is no report on substrate-specific inhibitors of OGT or OGA, largely due to the lack of suitable assays. Here, I propose to develop a novel high-throughput screening assay for identifying small molecules that can specifically bind to different regions of OGT and modulate O-GlcNAcylation of a particular protein of interest without perturbing the global O-GlcNAc level in cells. From the proposed screen and the following in vitro and cellular characterization and optimization processes, I expect to identify several compounds as the first generation of substrate-specific inhibitor candidates of OGT that can modulate O-GlcNAcylation on particular proteins related to aging diseases. This new assay platform can be potentially adapted for other protein substrates and facilitate the therapeutic development to combat aging disorders.

项目概要 O-连接 β-N-乙酰氨基葡萄糖 (O-GlcNAc) 是一种重要的翻译后修饰 在参与广泛的重要生物过程的数千种蛋白质中发现， 包括表观遗传学、代谢和蛋白质降解。 由一对人类酶 O-GlcNAc 转移酶动态添加和去除 (OGT) 和 O-GlcNAcase (OGA) 分别是 O-GlcNAc 的失调。 在许多与衰老相关的疾病中检测到，包括癌症、糖尿病、阿尔茨海默病和 迄今为止，已报道了几种有效的 OGT 活性位点抑制剂。 和 OGA，但它们可能会引起不良副作用，因为这些必需酶调节 目前，还没有关于O-GlcNAc对数千种蛋白质底物的动力学的报道。 OGT 或 OGA 的底物特异性抑制剂，很大程度上是由于缺乏合适的检测方法。 提议开发一种新的高通量筛选方法来鉴定小分子 可以特异性结合 OGT 的不同区域并调节特定的 O-GlcNAc 酰化 感兴趣的蛋白质，而不干扰细胞中的整体 O-GlcNAc 水平。 以及以下体外和细胞表征和优化过程，我希望 确定了几种化合物作为第一代底物特异性抑制剂候选物 OGT 可以调节与衰老疾病相关的特定蛋白质的 O-GlcNAc 酰化。 新的检测平台可能适用于其他蛋白质底物并促进 对抗衰老疾病的治疗方法的开发。